Literature DB >> 19047108

Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma.

Vanita K Gupta1, Andrew Feber, Liqiang Xi, Arjun Pennathur, Maoxin Wu, James D Luketich, Tony E Godfrey.   

Abstract

PURPOSE: Cyclin D1 is found on 11q13, which is a region frequently amplified in several tumor types. The CCND1 locus gives rise to at least two protein isoforms of D1 (D1a and D1b). A common G/A polymorphism (G/A870) is thought to influence the expression levels of D1a and D1b. D1b has been suggested to be increased in the presence of the A allele and more oncogenic than D1a. Furthermore, the A allele has been reported to correlate with increased risk of carcinoma in several tumor types, suggesting that this polymorphism and D1b are important in tumor progression. However, contradictory data about the polymorphism, D1 variant expression, and correlation with survival have been reported. We explored the relationship between gene amplification, G/A870 genotype, D1a and D1b expression, and overall survival in esophageal adenocarcinoma and non-small cell lung cancer. EXPERIMENTAL
DESIGN: DNA and RNA were isolated from 54 esophageal adenocarcinoma samples and 89 non-small cell lung cancer samples and were analyzed for gene amplification, genotype at the polymorphism, gene expression, and association with overall survival.
RESULTS: The D1 variant expression did not correlate with amplification, genotype, or overall survival in either tumor type. The total D1 expression correlated with decreased patient survival. Several other genes on 11q13 also seem to be overexpressed and correlated with decreased survival.
CONCLUSIONS: We report that the G/A870 polymorphism does not correlate with patient survival, or with D1a or D1b expression. However, the total D1 expression and the expression of several other genes on 11q13 seem to be associated with esophageal adenocarcinoma patient survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047108      PMCID: PMC2723959          DOI: 10.1158/1078-0432.CCR-08-0744

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  44 in total

1.  The clonal evolution of tumor cell populations.

Authors:  P C Nowell
Journal:  Science       Date:  1976-10-01       Impact factor: 47.728

2.  Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer.

Authors:  Loïc Le Marchand; Ann Seifried; Annette Lum-Jones; Timothy Donlon; Lynne R Wilkens
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

3.  A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line.

Authors:  D E Lebwohl; R Muise-Helmericks; L Sepp-Lorenzino; S Serve; M Timaul; R Bol; P Borgen; N Rosen
Journal:  Oncogene       Date:  1994-07       Impact factor: 9.867

4.  A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer.

Authors:  Justin Lamb; Sridhar Ramaswamy; Heide L Ford; Bernardo Contreras; Robert V Martinez; Frances S Kittrell; Cynthia A Zahnow; Nick Patterson; Todd R Golub; Mark E Ewen
Journal:  Cell       Date:  2003-08-08       Impact factor: 41.582

5.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins.

Authors:  P W Hinds; S Mittnacht; V Dulic; A Arnold; S I Reed; R A Weinberg
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

6.  Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.

Authors:  D E Quelle; R A Ashmun; S A Shurtleff; J Y Kato; D Bar-Sagi; M F Roussel; C J Sherr
Journal:  Genes Dev       Date:  1993-08       Impact factor: 11.361

7.  Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.

Authors:  David A Solomon; Ying Wang; Sejal R Fox; Tah C Lambeck; Sarah Giesting; Zhengdao Lan; Adrian M Senderowicz; Claudio J Conti; Erik S Knudsen
Journal:  J Biol Chem       Date:  2003-05-12       Impact factor: 5.157

Review 8.  Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer.

Authors:  C Dickson; V Fantl; C Gillett; S Brookes; J Bartek; R Smith; C Fisher; D Barnes; G Peters
Journal:  Cancer Lett       Date:  1995-03-23       Impact factor: 8.679

9.  The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer.

Authors:  Peter Krippl; Uwe Langsenlehner; Wilfried Renner; Babak Yazdani-Biuki; Gerald Wolf; Thomas C Wascher; Bernhard Paulweber; Werner Weitzer; Andreas Leithner; Hellmut Samonigg
Journal:  Breast Cancer Res Treat       Date:  2003-12       Impact factor: 4.872

10.  Human D-type cyclin.

Authors:  Y Xiong; T Connolly; B Futcher; D Beach
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

View more
  8 in total

1.  CCND1 G870A polymorphism interaction with cigarette smoking increases lung cancer risk: meta-analyses based on 5008 cases and 5214 controls.

Authors:  Yu-Zhong Duan; Liang Zhang; Chang-Chih Liu; Bo Zhu; Wen-Lei Zhuo; Zheng-Tang Chen
Journal:  Mol Biol Rep       Date:  2013-05-08       Impact factor: 2.316

2.  G870A Polymorphic Variants of CCND1 Gene and Cyclin D1 Protein Expression as Prognostic Markers in Laryngeal Lesions.

Authors:  Magdalena Marianna Kowalczyk; Magda Barańska; Wojciech Fendler; Edyta M Borkowska; Józef Kobos; Maciej Borowiec; Wioletta Pietruszewska
Journal:  Diagnostics (Basel)       Date:  2022-04-23

3.  Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.

Authors:  E K A Millar; J L Dean; C M McNeil; S A O'Toole; S M Henshall; T Tran; J Lin; A Quong; C E S Comstock; A Witkiewicz; E A Musgrove; H Rui; L Lemarchand; V W Setiawan; C A Haiman; K E Knudsen; R L Sutherland; E S Knudsen
Journal:  Oncogene       Date:  2009-03-16       Impact factor: 9.867

4.  Candidate gene association study of esophageal squamous cell carcinoma in a high-risk region in Iran.

Authors:  Mohammad R Akbari; Reza Malekzadeh; Ramin Shakeri; Dariush Nasrollahzadeh; Maryam Foumani; Yulong Sun; Akram Pourshams; Alireza Sadjadi; Elham Jafari; Masoud Sotoudeh; Farin Kamangar; Paolo Boffetta; Sanford M Dawsey; Parviz Ghadirian; Steven A Narod
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

Review 5.  The double dealing of cyclin D1.

Authors:  Guergana Tchakarska; Brigitte Sola
Journal:  Cell Cycle       Date:  2019-12-29       Impact factor: 4.534

6.  Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population.

Authors:  Zhenzhen Zeng; Jing Tu; Jin Cheng; Mingjie Yao; Yali Wu; Xiangbo Huang; Xiaomeng Xie; Xiaolei Zhang; Fengmin Lu; Xiangmei Chen
Journal:  Tumour Biol       Date:  2015-04-08

7.  CCND1 Splice Variant as A Novel Diagnostic and Predictive Biomarker for Thyroid Cancer.

Authors:  Sora Jeon; Yourha Kim; Young Mun Jeong; Ja Seong Bae; Chan Kwon Jung
Journal:  Cancers (Basel)       Date:  2018-11-13       Impact factor: 6.639

8.  Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.

Authors:  Francis R LeBlanc; Zainul S Hasanali; August Stuart; Sara Shimko; Kamal Sharma; Violetta V Leshchenko; Samir Parekh; Haiqing Fu; Ya Zhang; Melvenia M Martin; Mark Kester; Todd Fox; Jiangang Liao; Thomas P Loughran; Juanita Evans; Jeffrey J Pu; Stephen E Spurgeon; Mirit I Aladjem; Elliot M Epner
Journal:  Oncotarget       Date:  2022-08-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.